Caribou Biosciences winds down after failing to fund late-stage CAR-T trial
- STAT reports the Doudna co-founded company is shutting down after failing to raise the money needed for a late-stage trial of its off-the-shelf CAR-T therapy for lymphoma.
- Other coverage describes the company stopping development of its two clinical cell therapy candidates and cutting most staff while exploring a merger or sale.
- Only the public STAT+ summary was available, so details beyond that are unverified.
💡 Points
A flagship CRISPR-era CAR-T name folding over a funding gap says the off-the-shelf cell therapy thesis is struggling to raise money against autologous products and bispecifics. It reads more as a financing failure than a clean scientific verdict, so watch whether the assets and data find a buyer.
STAT+: Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down ↗